| CTRI Number |
CTRI/2025/08/093540 [Registered on: 25/08/2025] Trial Registered Prospectively |
| Last Modified On: |
24/08/2025 |
| Post Graduate Thesis |
No |
| Type of Trial |
Interventional |
|
Type of Study
|
Homeopathy |
| Study Design |
Single Arm Study |
|
Public Title of Study
|
A prospective open labelled clinical trial to assess the role of Homoepathic medicines in Cholelithiasis |
|
Scientific Title of Study
|
A prospective open labelled clinical trial to assess the role of Homoeopathic medicines in Cholelithiasis |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
DrPartha Pratim Pal |
| Designation |
Research Officer (Homoeopathy) Scientist - 2 |
| Affiliation |
Central Council for Research in Homoeopathy |
| Address |
Dr Anjali Chatterji Regional Research Institute for Homoeopathy
Department of Clinical Research
Room no 5 50 Rajendra Chatterjee Road, Kolkata WEST BENGAL 700035 India |
| Phone |
8910890779 |
| Fax |
|
| Email |
justdoit.partha007@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
DrPartha Pratim Pal |
| Designation |
Research Officer (Homoeopathy) Scientist - 2 |
| Affiliation |
Central Council for Research in Homoeopathy |
| Address |
Dr Anjali Chatterji Regional Research Institute for Homoeopathy
Department of Clinical Research
Room no 5 50 Rajendra Chatterjee Road,
WEST BENGAL 700035 India |
| Phone |
8910890779 |
| Fax |
|
| Email |
justdoit.partha007@gmail.com |
|
Details of Contact Person Public Query
|
| Name |
DrPartha Pratim Pal |
| Designation |
Research Officer (Homoeopathy) Scientist - 2 |
| Affiliation |
Central Council for Research in Homoeopathy |
| Address |
Dr Anjali Chatterji Regional Research Institute for Homoeopathy
Department of Clinical Research
Room no 5 50 Rajendra Chatterjee Road,
WEST BENGAL 700035 India |
| Phone |
8910890779 |
| Fax |
|
| Email |
justdoit.partha007@gmail.com |
|
|
Source of Monetary or Material Support
|
| Director General, Central Council for Research in
Homoeopathy
61-65, Institutional Area, Opp. ‘D’ Block, Janak Puri, New Delhi – 110058, India. |
|
|
Primary Sponsor
|
| Name |
Director General, Central Council for Research in Homoeopathy |
| Address |
61-65, Institutional Area, Opp. ‘D’ Block, Janak Puri, New Delhi 110058 |
| Type of Sponsor |
Research institution |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| DrPartha Pratim Pal |
Dr Anjali Chatterji Chatterji Regional Research Institute for Homoeopathy, Kolkata |
Department of Clinical Research
Room no 5
50 Rajendra Chatterjee Road
Baranagar
Kolkata 700035 North Twentyfour Parganas WEST BENGAL |
8910890779
justdoit.partha007@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Instituitional Ethics Committee of Dr Anjali Chatterji Chatterji Regional Research Institute for Homoeopathy, Kolkata |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: K80||Cholelithiasis, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Homoeopathic medicines |
Indicated homoeopathic medicine as per symptom similarity would be selected on the basis of totality of symptoms, followed by repertorization. Selected medicine would be prescribed in 6C potency and to be given orally at the start of the treatment. Dosage schedule will be as per requirement of the case. During the period of the study, the potency would be raised sequentially as per the need of the case, in pursuance with the homoeopathic principles. |
| Comparator Agent |
Not applicable |
Single arm study |
|
|
Inclusion Criteria
|
| Age From |
20.00 Year(s) |
| Age To |
60.00 Year(s) |
| Gender |
Both |
| Details |
• Patient with or without symptoms of upper abdominal pain and tenderness, nausea, vomiting, jaundice, or other dyspeptic features but having evidence of gallstones (single or multiple) or gall bladder sludge with average diameter less than or equal to 15 mm or showing contracted GB or partially contracted GB in Upper abdominal USG. |
|
| ExclusionCriteria |
| Details |
Complicated Cholelithiasis i.e. for example cases which need immediate surgical intervention and complications like obstructive jaundice perforation fistula empyema gangrene carcinoma liver failure cholangitis gallstone ileus or pancreatitis or any related serious complications.
Acute cholecystitis with ASA classification greater than III
Cirrhosis of Liver
Malignancy
Pregnant and lactating women
|
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Open Label |
|
Primary Outcome
|
| Outcome |
TimePoints |
| To evaluate the response of homoeopathic medicines by comparing the assessing status of Cholelithiasis (absent or present/ if still present _ increased, decreased or status quo) and gall bladder thickness via Upper abdominal USG at baseline, 6 months and 12 months and also assessing the symptoms of the patient via GSS (Gall stone symptom score)16at baseline, 3 months, 6 months, 9 months and 12 months. |
Baseline 6month 12month |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| To assess the quality of life using The Gastrointestinal Quality of Life Index (GIQLI) 17which includes both specific questions on gastrointestinal symptoms, for both the upper and lower digestive tracts, as well as generic questions on physical, emotional, and social capabilities and also comparing the parameters of LFT and Lipid profile (at baseline, 6 months, 12 months). |
Baseline 6month 12month |
|
|
Target Sample Size
|
Total Sample Size="30" Sample Size from India="30"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
Phase 2 |
|
Date of First Enrollment (India)
|
07/11/2025 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="3" Months="0" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Yet Recruiting |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - YES
- What data in particular will be shared?
Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
- What additional supporting information will be shared?
Response - Study Protocol Response - Statistical Analysis Plan Response - Informed Consent Form
- Who will be able to view these files?
Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.
- For what types of analyses will this data be available?
Response - To achieve aims in the approved proposal.
- By what mechanism will data be made available?
Response - Proposals should be directed to [justdoit.partha007@gmail.com].
- For how long will this data be available start date provided 01-12-2029 and end date provided 31-12-2034?
Response - Immediately following publication. No end date.
- Any URL or additional information regarding plan/policy for sharing IPD?
Additional Information - NIL
|
|
Brief Summary
|
Cholelithiasis is a common chronic disease of the hepatobiliary system in India which may be symptomatic or asymptomatic. The prevalence of cholelithiasis varies and has been reported as 2-29% in India, and increased in the recent years. The majority of gallstones are asymptomatic and merely 10% of these may develop symptoms. Hence, most gallstones are clinically “silent,” and an accidental finding often uncovered during abdominal ultrasound being performed for another reason. Symptomatic gallstones manifest either as biliary pain/colic or cholecystitis. They may experience intense pain in the upper-right side of the abdomen, often accompanied by nausea and vomiting, that steadily increases for approximately 30 min to several hours. Along with these non-specific symptoms They include the isolated heartburn, acid regurgitation, belching, nausea, vomiting, bloating, abdominal distention, chest pain, postprandial fullness or early satiety and flatulence may also be present. On examination patients may have jaundice and right quadrant tenderness may be present with palpitation, a positive Murphy sign may be elicited. Often, attacks occur after a particularly fatty meal and almost always happen at night. Ultrasonography has a specificity and sensitivity of 90-95%, and can detect stones as small as 2 mm in diameter. Although Cholecystectomy is the gold-standard for Cholelithiasis, routine Cholecystectomy for all subjects with silent gallstones or mild symptoms is always not necessary. Cholelithiasis cases do frequently come to homoeopathic clinics. Time and again, Homoeopathy has proved effective in treatment of gall bladder stones. Inspite of published evidence-based cases reports, clinical trials related to gallstones is lacking and hence needs to be designed. This prospective, open-labelled clinical trial is designed to assess the efficacy of homoeopathic medicines in cholelithiasis cases. For evaluation ultrasonography will be done at base line, 6th and 12th month along with LFT and Lipid profile. Quality of life will be assessed via Gastrointestinal Quality of Life Index (GIQLI) at baseline, 6th month and 12th month. Indicated homoeopathic medicine as per symptom similarity would be selected on the basis of totality of symptoms, followed by repertorization. Selected medicine would be prescribed in 6C potency at the start of the treatment. Dosage schedule will be as per requirement of the case. During the period of the study, the potency would be raised sequentially as per the need of the case, in pursuance with the homoeopathic principles. |